NANEXA — Nanexa AB Share News
0.000.00%
Last trade - 00:00- SEK676.32m
- SEK604.28m
- SEK36.15m
Brief: Nanexa Q1 EBIT SEK -13.61 Million
Brief: Nanexa Gets About SEK 55.7 Mln From Exercise Of Warrants
Brief: Nanexa Demonstrates Quarterly Semaglutide Dosing Feasibility
Sweden's Nanexa Q4 revenue jumps
Brief: Nanexa Q4 Revenue SEK At 30.1 Mln
Brief: Nanexa Announces Preclinical Results For Semaglutide Formulation
Brief: Nanexa Q3 EBIT SEK -11.983 Million
Brief: Nanexa Receives Japanese Patent Approval
Brief: Nanexa Q2 EBIT Loss Of SEK 5.2 Mln
Brief: Nanexa 30 Mg Nex-22 Shows 36-Day Exposure Without Significant GI Side Effects
Brief: Nanexa Ends Collaboration With Applied Materials
Brief: Nanexa Q1 EBIT SEK -8.213 Million
Brief: Nanexa Says NEX-22 30 Mg Dose Well Tolerated In Phase I Study
Brief: Nanexa Proposes No Dividend For 2024
Brief: Nanexa Q4 EBIT SEK -12.025 Million
Brief: Nanexa To Resume Phase I Study With Nex-22 With Further Dose Escalation
Brief: Nanexa Carries Out Directed Issue Of Units
Brief: Nanexa Comments On News About License On Long-Acting Technology Platform
Advisory: Alerts on Nanexa progress, revaluation and financing withdrawn